<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02442466</url>
  </required_header>
  <id_info>
    <org_study_id>MelCure</org_study_id>
    <nct_id>NCT02442466</nct_id>
  </id_info>
  <brief_title>Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>MelCure SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MelCure SA</source>
  <brief_summary>
    <textblock>
      Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788) or vehicle was
      preformed in 5 melanoma patients to have a preliminary analysis of safety, dose, duration and
      relevance of results observed in pre-clinical studies to the human disease.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulties to recruit on time the required patient population.
  </why_stopped>
  <start_date>May 2011</start_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumour response by size measurement and histological examination</measure>
    <time_frame>3 to14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measuring changes in tumor cell proliferation by histological analyses using Ab staining</measure>
    <time_frame>3 to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of changes in mRNA as well as protein expression levels of Endothelin Receptor B by PCR and Ab staining</measure>
    <time_frame>3 to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of changes in blood vessels formation by histological examination using Ab staining</measure>
    <time_frame>3 to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of changes in immune cell infiltration by histological examination using Ab staining</measure>
    <time_frame>3 to 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Endothelin receptor B inhibitor BQ-788</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-lesion administration of vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endothelin Receptor B inhibitor BQ788</intervention_name>
    <arm_group_label>Endothelin receptor B inhibitor BQ-788</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBS</intervention_name>
    <arm_group_label>PBS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written Informed consent

          -  Histologically confirmed melanoma

          -  Disease stage III or IV

          -  At least 2 injectable and surgically removable cutaneous metastasis

          -  Age &gt; 18 years

          -  Clinically stable medical condition

        Exclusion Criteria:

          -  Primary ocular melanoma

          -  Symptomatic intracranial melanoma

          -  History of severe neurological, cardiovascular, renal, hepatic, endocrinological,
             respiratory, bone marrow, autoimmune or infectious (HIV) disease

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Lahav R, Ziller C, Dupin E, Le Douarin NM. Endothelin 3 promotes neural crest cell proliferation and mediates a vast increase in melanocyte number in culture. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3892-7.</citation>
    <PMID>8632985</PMID>
  </reference>
  <reference>
    <citation>Lahav R, Dupin E, Lecoin L, Glavieux C, Champeval D, Ziller C, Le Douarin NM. Endothelin 3 selectively promotes survival and proliferation of neural crest-derived glial and melanocytic precursors in vitro. Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14214-9.</citation>
    <PMID>9826680</PMID>
  </reference>
  <reference>
    <citation>Lahav R, Heffner G, Patterson PH. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11496-500.</citation>
    <PMID>10500205</PMID>
  </reference>
  <reference>
    <citation>Lahav R, Suv√† ML, Rimoldi D, Patterson PH, Stamenkovic I. Endothelin receptor B inhibition triggers apoptosis and enhances angiogenesis in melanomas. Cancer Res. 2004 Dec 15;64(24):8945-53.</citation>
    <PMID>15604257</PMID>
  </reference>
  <reference>
    <citation>Lahav R. Endothelin receptor B is required for the expansion of melanocyte precursors and malignant melanoma. Int J Dev Biol. 2005;49(2-3):173-80. Review.</citation>
    <PMID>15906230</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2015</study_first_submitted>
  <study_first_submitted_qc>May 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2015</study_first_posted>
  <last_update_submitted>May 18, 2015</last_update_submitted>
  <last_update_submitted_qc>May 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BQ 788</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

